Olulade Ayodele

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.

Introduction Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE), is a common condition that continues to be an important cause of morbidity and mortality.1 In the United States, over half a million VTE events are treated yearly, with mortality rates as high as 1–6% for DVT and 12–23% for PE.

Abstract and Introduction Abstract Objective: This study assessed the risk of developing chronic kidney disease (CKD) and decline in estimated glomerular filtration rate (eGFR) over a period of up to 5 years in adult patients with chronic hypoparathyroidism treated with recombinant human parathyroid hormone (1–84) (rhPTH[1–84]) compared with a historical control cohort of patients not treated with rhPTH(1–84).